vs
Side-by-side financial comparison of HUTCHMED (China) Ltd (HCM) and Xometry, Inc. (XMTR). Click either name above to swap in a different company.
HUTCHMED (China) Ltd is the larger business by last-quarter revenue ($270.8M vs $192.4M, roughly 1.4× Xometry, Inc.). HUTCHMED (China) Ltd runs the higher net margin — 0.7% vs -4.5%, a 5.2% gap on every dollar of revenue. On growth, Xometry, Inc. posted the faster year-over-year revenue change (29.5% vs -16.5%). HUTCHMED (China) Ltd produced more free cash flow last quarter ($3.4M vs $-5.9M).
HUTCHMED (China) LtdHCMEarnings & Financial Report
HUTCHMED (China) Ltd is a biopharmaceutical firm focused on discovering, developing and commercializing targeted and immunotherapies for oncology and immunological diseases. It operates across China and global markets, with multiple marketed oncology drugs and a robust pipeline of late-stage clinical candidates addressing unmet patient needs.
Xometry is an online marketplace for sourcing on-demand manufactured parts for prototyping and large-scale production.
HCM vs XMTR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $270.8M | $192.4M |
| Net Profit | $2.0M | $-8.6M |
| Gross Margin | 37.7% | 39.1% |
| Operating Margin | -13.2% | -4.6% |
| Net Margin | 0.7% | -4.5% |
| Revenue YoY | -16.5% | 29.5% |
| Net Profit YoY | -83.6% | 12.7% |
| EPS (diluted) | $0.00 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $270.8M | $192.4M | ||
| Q3 25 | — | $180.7M | ||
| Q2 25 | $277.7M | $162.5M | ||
| Q1 25 | $324.5M | $151.0M | ||
| Q4 24 | — | $148.5M | ||
| Q3 24 | — | $141.7M | ||
| Q2 24 | $305.7M | $132.6M | ||
| Q1 24 | — | $122.7M |
| Q4 25 | $2.0M | $-8.6M | ||
| Q3 25 | — | $-11.6M | ||
| Q2 25 | $455.0M | $-26.4M | ||
| Q1 25 | $11.9M | $-15.1M | ||
| Q4 24 | — | $-9.9M | ||
| Q3 24 | — | $-10.2M | ||
| Q2 24 | $25.8M | $-13.7M | ||
| Q1 24 | — | $-16.6M |
| Q4 25 | 37.7% | 39.1% | ||
| Q3 25 | — | 39.9% | ||
| Q2 25 | 0.1% | 40.1% | ||
| Q1 25 | 48.0% | 37.3% | ||
| Q4 24 | — | 39.7% | ||
| Q3 24 | — | 39.4% | ||
| Q2 24 | 41.1% | 39.9% | ||
| Q1 24 | — | 39.0% |
| Q4 25 | -13.2% | -4.6% | ||
| Q3 25 | — | -6.1% | ||
| Q2 25 | -1.3% | -6.3% | ||
| Q1 25 | -5.0% | -10.2% | ||
| Q4 24 | — | -7.8% | ||
| Q3 24 | — | -8.1% | ||
| Q2 24 | -9.0% | -11.5% | ||
| Q1 24 | — | -14.6% |
| Q4 25 | 0.7% | -4.5% | ||
| Q3 25 | — | -6.4% | ||
| Q2 25 | 163.8% | -16.3% | ||
| Q1 25 | 3.7% | -10.0% | ||
| Q4 24 | — | -6.7% | ||
| Q3 24 | — | -7.2% | ||
| Q2 24 | 8.4% | -10.3% | ||
| Q1 24 | — | -13.5% |
| Q4 25 | $0.00 | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $0.52 | — | ||
| Q1 25 | $0.01 | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $0.03 | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | $219.1M |
| Total DebtLower is stronger | $93.2M | — |
| Stockholders' EquityBook value | $1.2B | $275.6M |
| Total Assets | $1.8B | $703.7M |
| Debt / EquityLower = less leverage | 0.08× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | $219.1M | ||
| Q3 25 | — | $224.5M | ||
| Q2 25 | $1.4B | $225.8M | ||
| Q1 25 | $836.1M | $231.4M | ||
| Q4 24 | — | $239.8M | ||
| Q3 24 | — | $234.0M | ||
| Q2 24 | $802.5M | $240.9M | ||
| Q1 24 | — | $253.8M |
| Q4 25 | $93.2M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $93.4M | — | ||
| Q1 25 | $82.8M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $82.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $1.2B | $275.6M | ||
| Q3 25 | — | $272.0M | ||
| Q2 25 | $1.2B | $270.4M | ||
| Q1 25 | $759.9M | $309.9M | ||
| Q4 24 | — | $314.5M | ||
| Q3 24 | — | $315.2M | ||
| Q2 24 | $740.1M | $315.8M | ||
| Q1 24 | — | $320.4M |
| Q4 25 | $1.8B | $703.7M | ||
| Q3 25 | — | $698.9M | ||
| Q2 25 | $1.8B | $687.0M | ||
| Q1 25 | $1.3B | $690.1M | ||
| Q4 24 | — | $680.1M | ||
| Q3 24 | — | $678.2M | ||
| Q2 24 | $1.3B | $678.6M | ||
| Q1 24 | — | $692.5M |
| Q4 25 | 0.08× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.08× | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.11× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $8.2M | $4.4M |
| Free Cash FlowOCF − Capex | $3.4M | $-5.9M |
| FCF MarginFCF / Revenue | 1.2% | -3.0% |
| Capex IntensityCapex / Revenue | 1.8% | 5.3% |
| Cash ConversionOCF / Net Profit | 4.21× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-96.2M | $-24.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $8.2M | $4.4M | ||
| Q3 25 | — | $5.8M | ||
| Q2 25 | $-72.9M | $-427.0K | ||
| Q1 25 | $40.3M | $-3.7M | ||
| Q4 24 | — | $9.1M | ||
| Q3 24 | — | $-3.6M | ||
| Q2 24 | $-39.8M | $-9.1M | ||
| Q1 24 | — | $-11.7M |
| Q4 25 | $3.4M | $-5.9M | ||
| Q3 25 | — | $-1.7M | ||
| Q2 25 | $-82.2M | $-7.4M | ||
| Q1 25 | $32.5M | $-9.2M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | — | $-8.4M | ||
| Q2 24 | $-49.9M | $-13.5M | ||
| Q1 24 | — | $-16.1M |
| Q4 25 | 1.2% | -3.0% | ||
| Q3 25 | — | -0.9% | ||
| Q2 25 | -29.6% | -4.5% | ||
| Q1 25 | 10.0% | -6.1% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | — | -6.0% | ||
| Q2 24 | -16.3% | -10.2% | ||
| Q1 24 | — | -13.1% |
| Q4 25 | 1.8% | 5.3% | ||
| Q3 25 | — | 4.1% | ||
| Q2 25 | 3.3% | 4.3% | ||
| Q1 25 | 2.4% | 3.6% | ||
| Q4 24 | — | 3.1% | ||
| Q3 24 | — | 3.4% | ||
| Q2 24 | 3.3% | 3.3% | ||
| Q1 24 | — | 3.5% |
| Q4 25 | 4.21× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.16× | — | ||
| Q1 25 | 3.38× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -1.54× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HCM
Segment breakdown not available.
XMTR
| US | $159.1M | 83% |
| Non Us | $33.3M | 17% |
